Neurokinin 2-R in medial septum regulate hippocampal and amygdalar ACh release induced by intraseptal application of neurokinins A and B

Hippocampus

Volumn 22, Issue 5, 2012, Pages 1058-1067

  Schäble, Sandra ^a   Huston, Joseph P ^a   De Souza Silva, Maria A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Amygdala; Frontal cortex; Hippocampus; In vivo microdialysis; NK receptors; Rat; SR48968

Indexed keywords

ACETYLCHOLINE; NEUROKININ 2 RECEPTOR; NEUROKININ A; NEUROKININ B; SAREDUTANT; BENZAMIDE DERIVATIVE; NEUROKININ 3 RECEPTOR; PIPERIDINE DERIVATIVE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; FOREBRAIN; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; ANALYSIS OF VARIANCE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FRONTAL LOBE; MEMORY; METABOLISM; SEPTUM NUCLEUS; SEPTUM PELLUCIDUM; WISTAR RAT;

ACETYLCHOLINE; AMYGDALA; ANALYSIS OF VARIANCE; ANIMALS; BENZAMIDES; CHOLINERGIC NEURONS; FRONTAL LOBE; HIPPOCAMPUS; MALE; MEMORY; NEUROKININ A; NEUROKININ B; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-2; RECEPTORS, NEUROKININ-3; SEPTAL NUCLEI; SEPTUM OF BRAIN;

EID: 84859702530     PISSN: 10509631     EISSN: 10981063     Source Type: Journal    
DOI: 10.1002/hipo.20847     Document Type: Article

References (52)

1. Acquas E, Wilson C, Fibiger HC. 1996. Conditioned and unconditioned stimuli increase frontal cortical and hippocampal acetylcholine release: Effects of novelty, habituation, and fear. J. Neurosci 16: 3089-3096.
2. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martin JD, Candenas ML. 2004. Tachykinins and tachykinin receptors: Structure and activity relationships. CurrMedChem 11: 2045-2081.
3. Aloisi AM, Casamenti F, Scali C, Pepeu G, Carli G. 1997. Effects of novelty, pain and stress on hippocampal extracellular acetylcholine levels in male rats. Brain Res 748: 219-226.
4. Alvaro G, Di Fabio R. 2007. Neurokinin 1 receptor antagonists-current prospects. CurrOpinDrug DiscovDevel 10: 613-621.
5. Arenas E, Alberch J, Perez-Navarro E, Solsona C, Marsal J. 1991. Neurokinin receptors differentially mediate endogenous acetylcholine release evoked by tachykinins in the neostriatum. J. Neurosci 11: 2332-2338.
6. Boix F, Pfister M, Huston JP, Schwarting RK. 1994. Substance P decreases extracellular concentrations of acetylcholine in neostriatum and nucleus accumbens in vivo: Possible relevance for the central processing of reward and aversion. Behav Brain Res 63: 213-219.
7. Calandreau L, Trifilieff P, Mons N, Costes L, Marien M, Marighetto A, Micheau J, Jaffard R, Desmedt A. 2006. Extracellular hippocampal acetylcholine level controls amygdala function and promotes adaptive conditioned emotional response. J Neurosci 26: 13556-13566.
8. Ceccarelli I, Casamenti F, Massafra C, Pepeu G, Scali C, Aloisi AM. 1999. Effects of novelty and pain on behavior and hippocampal extracellular ACh levels in male and female rats. Brain Res 815: 169-176.
9. Chen LW, Wei LC, Liu HL, Ding YQ, Zhang H, Rao ZR, Ju G, Chan YS. 2001a. Cholinergic neurons expressing neuromedin K receptor (NK3) in the basal forebrain of the rat: A double immunofluorescence study. Neuroscience 103: 413-422.
10. Chen LW, Wei LC, Liu HL, Qiu Y, Chan YS. 2001b. Cholinergic neurons expressing substance P receptor (NK(1)) in the basal forebrain of the rat: A double immunocytochemical study. Brain Res 904: 161-166.
11. Dam TV, Escher E, Quirion R. 1990. Visualization of neurokinin-3 receptor sites in rat brain using the highly selective ligand [3H]senktide. Brain Res 506: 175-179.
12. Damsma G, Westerink BH, Imperato A, Rollema H, de Vries JB, Horn AS. 1987. Automated brain dialysis of acetylcholine in freely moving rats: Detection of basal acetylcholine. Life Sci 41: 873-876.
13. De Souza Silva MA, Hasenohrl RU, Tomaz C, Schwarting RK, Huston JP. 2000. Differential modulation of frontal cortex acetylcholine by injection of substance P into the nucleus basalis magnocellularis region in the freely-moving vs. the anesthetized preparation.Synapse 38: 243-253.
14. Desvignes C, Rouquier L, Souilhac J, Mons G, Rodier D, Soubrie P, Steinberg R. 2003. Control by tachykinin NK(2) receptors of CRF(1) receptor-mediated activation of hippocampal acetylcholine release in the rat and guinea-pig. Neuropeptides 37: 89-97.
15. Ding YQ, Shigemoto R, Takada M, Ohishi H, Nakanishi S, Mizuno N. 1996. Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat. J Comp Neurol 364: 290-310.
16. Duarte CR, Schutz B, Zimmer A. 2006. Incongruent pattern of neurokinin B expression in rat and mouse brains. Cell Tissue Res 323: 43-51.
17. Emonds-Alt X, Vilain P, Goulaouic P, Proietto V, Van BD, Advenier C, Naline E, Neliat G, Le FG, Breliere JC. 1992. A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci 50: L101-L106.
18. Giovannini MG, Bartolini L, Kopf SR, Pepeu G. 1998. Acetylcholine release from the frontal cortex during exploratory activity. Brain Res 784: 218-227.
19. Griebel G. 1999. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 82: 1-61.
20. Griebel G, Moindrot N, Aliaga C, Simiand J, Soubrie P. 2001a. Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neurosci Biobehav Rev 25: 619-626.
21. Griebel G, Perrault G, Soubrie P. 2001b. Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents. Psychopharmacology (Berl) 158: 241-251.
22. Hagan RM, Beresford IJ, Stables J, Dupere J, Stubbs CM, Elliott PJ, Sheldrick RL, Chollet A, Kawashima E, McElroy AB. 1993. Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists. Regul Pept 46: 9-19.
23. Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G. 2003. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24: 580-588.
24. Imperato A, Puglisi-Allegra S, Casolini P, Angelucci L. 1991. Changes in brain dopamine and acetylcholine release during and following stress are independent of the pituitary-adrenocortical axis. Brain Res 538: 111-117.
25. Inglis FM, Fibiger HC. 1995. Increases in hippocampal and frontal cortical acetylcholine release associated with presentation of sensory stimuli. Neuroscience 66: 81-86.
26. Kameyama T, Ukai M, Shinkai N. 1998. Ameliorative effects of tachykinins on scopolamine-induced impairment of spontaneous alternation performance in mice. Methods Find Exp Clin Pharmacol 20: 555-560.
27. Liu H, Brown JL, Jasmin L, Maggio JE, Vigna SR, Mantyh PW, Basbaum AI. 1994. Synaptic relationship between substance P, the substance P receptor: Light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. ProcNatlAcadSciUSA 91: 1009-1013.
28. Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G. 2008. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 89: 36-45.
29. Maeno H, Kiyama H, Tohyama M. 1993. Distribution of the substance P receptor (NK-1 receptor) in the central nervous system. Brain Res Mol Brain Res 18: 43-58.
30. Marco N, Thirion A, Mons G, Bougault I, Le Fur G, Soubrie P, Steinberg R. 1998. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: An in vivo microdialysis approach in guinea pig. Neuropeptides 32: 481-488.
31. Micale V, Tamburella A, Leggio GM, Mazzola C, Li V, V, Drago F. 2008. Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol Biochem Behav 90: 463-469.
32. Mileusnic D, Lee JM, Magnuson DJ, Hejna MJ, Krause JE, Lorens JB, Lorens SA. 1999. Neurokinin-3 receptor distribution in rat and human brain: An immunohistochemical study. Neuroscience 89: 1269-1290.
33. Moore H, Sarter M, Bruno JP. 1992. Age-dependent modulation of in vivo cortical acetylcholine release by benzodiazepine receptor ligands. Brain Res 596: 17-29.
34. Morozova E, Wu M, Dumalska I, Alreja M. 2008. Neurokinins robustly activate the majority of septohippocampal cholinergic neurons. Eur J Neurosci 27: 114-122.
35. Nilsson OG, Kalen P, Rosengren E, Bjorklund A. 1990. Acetylcholine release in the rat hippocampus as studied by microdialysis is dependent on axonal impulse flow and increases during behavioural activation. Neuroscience 36: 325-338.
36. Paxinos G, Watson C. 1986. The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press.
37. Potter PE, Meek JL, Neff NH. 1983. Acetylcholine and choline in neuronal tissue measured by HPLC with electrochemical detection. J Neurochem 41: 188-194.
38. Ribeiro SJ, Teixeira RM, Calixto JB, De Lima TC. 1999. Tachykinin NK(3)receptor involvement in anxiety. Neuropeptides 33: 181-188.
39. Rosenblad C, Nilsson OG. 1993. Basal forebrain grafts in the rat neocortex restore in vivo acetylcholine release and respond to behavioural activation. Neuroscience 55: 353-362.
40. Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. 2001. Presence of NK2 binding sites in the rat brain. J. Neurochem 79: 985-996.
41. Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. 2003. Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: Comparison with NK1 and NK3 binding sites. Neuroscience 116: 761-773.
42. Salome N, Stemmelin J, Cohen C, Griebel G. 2006. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacol Biochem Behav 83: 533-539.
43. Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GA, Hay DW. 1997. Nonpeptide tachykinin receptor antagonists. I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther 281: 1303-1311.
44. Schäble S, Huston JP, Brandao ML, Dere E, De Souza Silva MA. 2010. Neurokinin-2 receptor antagonism in medial septum influences temporal-order memory for objects and forebrain cholinergic activity. Peptides 31: 108-115.
45. Shughrue PJ, Lane MV, Merchenthaler I. 1996. In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J Comp Neurol 372: 395-414.
46. Steinberg R, Rodier D, Souiclhac J, Bougault I, Emonds-Alt X, Soubrie P, Le Fur G. 1995. Pharmacological characterization of tachykinin receptors controlling acetylcholine release from rat striatum: an in vivo microdialysis study. J. Neurochem 65: 2543-2548.
47. Steinberg R, Marco N, Voutsinos B, Bensaid M, Rodier D, Souilhac J, Alonso R, Oury-Donat F, Le Fur G, Soubrie P. 1998. Expression and presence of septal neurokinin-2 receptors controlling hippocampal acetylcholine release during sensory stimulation in rat. Eur J Neurosci 10: 2337-2345.
48. Stratton SC, Beresford IJ, Harvey FJ, Turpin MP, Hagan RM, Tyers MB. 1993. Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box. Eur J Pharmacol 250: R11-R12.
49. Teixeira RM, Santos AR, Ribeiro SJ, Calixto JB, Rae GA, De Lima TC. 1996. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311: 7-14.
50. Ukai M, Shinkai N, Kameyama T. 1998. Involvement of dopamine receptors in beneficial effects of tachykinins on scopolamine-induced impairment of alternation performance in mice. Eur J Pharmacol 350: 39-45.
51. Walsh DM, Stratton SC, Harvey FJ, Beresford IJ, Hagan RM. 1995. The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology (Berl) 121: 186-191.
52. Zlomuzica A, Dere E, Huston JP, De Souza Silva MA. 2008. NK(3) receptor agonism promotes episodic-like memory in mice. Neurobiol Learn Mem 90: 420-425.